论文部分内容阅读
目的 :对氯替泼诺控制眼部炎症的有效性和安全性进行系统评价。方法 :检索MEDLINE获得 8篇以往发表的论文 ,并根据临床和统计标准进行合并分析。通过计算优势比来评估氯替泼诺治疗的安全性和有效性 ,并按照固定效应模型对优势比进行合并。结果 :总计 1 660例病人纳入荟萃分析。与安慰剂和泼尼松龙相比 ,眼内压升高的合并危险差分别为 1 % (95 %可信区间 ,-1 % ,3 % ) ,-5 % (95 %可信区间 ,-9% ,0 % )。与安慰剂相比 ,炎症控制的合并危险差分别为 :术后炎症 3 1 %(95 %可信区间 ,2 2 % ,40 % ) ,春季结膜炎 2 8%(95 %可信区间 ,1 9% ,3 7% ) ,过敏性结膜炎 2 6%(95 %可信区间 ,1 8% ,3 5 % ) ;而与泼尼松龙相比 ,急性前葡萄膜炎控制的合并危险差为 -1 5 %(95 %可信区间 ,-2 5 % ,-4% )。结论 :氯替泼诺可以控制眼部炎症 ,如 :术后炎症、春季结膜炎、过敏性结膜炎、急性前葡萄膜炎 ,是既有效又安全的糖皮质激素
OBJECTIVE: To systematically evaluate the efficacy and safety of loteprednol in the control of ocular inflammation. METHODS: Eight MEDLINE previously searched papers were searched and pooled for analysis based on clinical and statistical criteria. The safety and efficacy of loteprednol as treatment was evaluated by calculating odds ratios and the odds ratios were combined according to the fixed effects model. RESULTS: A total of 1 660 patients were included in the meta-analysis. Compared with placebo and prednisolone, the combined risk of intraocular hypertension was 1% (95% confidence interval, -1%, 3%), -5% (95% confidence interval, - 9%, 0%). Compared with placebo, the difference in the risk of combination of inflammation control were: postoperative inflammation 31% (95% confidence interval, 22%, 40%), spring conjunctivitis 28% (95% confidence interval 1 9%, 37%), allergic conjunctivitis 26% (95% confidence interval, 18%, 35%); and compared with prednisolone, the risk of combined anterior uveitis control is poor Was -1 5% (95% confidence interval, -2 5%, -4%). CONCLUSIONS: Loteprednol eyedrops can control ocular inflammation such as postoperative inflammation, vernal conjunctivitis, allergic conjunctivitis, and anterior anterior uveitis, which are both potent and safe glucocorticoids